BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 10715300)

  • 1. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
    Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
    J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
    Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
    Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
    Mandelli F; Diverio D; Avvisati G; Luciano A; Barbui T; Bernasconi C; Broccia G; Cerri R; Falda M; Fioritoni G; Leoni F; Liso V; Petti MC; Rodeghiero F; Saglio G; Vegna ML; Visani G; Jehn U; Willemze R; Muus P; Pelicci PG; Biondi A; Lo Coco F
    Blood; 1997 Aug; 90(3):1014-21. PubMed ID: 9242531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto.
    Specchia G; Lo Coco F; Vignetti M; Avvisati G; Fazi P; Albano F; Di Raimondo F; Martino B; Ferrara F; Selleri C; Liso V; Mandelli F
    J Clin Oncol; 2001 Oct; 19(20):4023-8. PubMed ID: 11600603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
    Ono T; Takeshita A; Kishimoto Y; Kiyoi H; Okada M; Yamauchi T; Emi N; Horikawa K; Matsuda M; Shinagawa K; Monma F; Ohtake S; Nakaseko C; Takahashi M; Kimura Y; Iwanaga M; Asou N; Naoe T;
    Cancer Sci; 2014 Jan; 105(1):97-104. PubMed ID: 24206578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
    Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
    Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
    Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.
    Testi AM; Biondi A; Lo Coco F; Moleti ML; Giona F; Vignetti M; Menna G; Locatelli F; Pession A; Barisone E; De Rossi G; Diverio D; Micalizzi C; Aricò M; Basso G; Foa R; Mandelli F
    Blood; 2005 Jul; 106(2):447-53. PubMed ID: 15677559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
    Sobas M; Montesinos P; Boluda B; Bernal T; Vellenga E; Nomdedeu J; González-Campos J; Chillón M; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil-Cortes C; Tormo M; Salamero O; Manso F; Fernández I; de la Serna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA;
    Leuk Lymphoma; 2019 Apr; 60(4):1030-1035. PubMed ID: 30322324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.
    Latagliata R; Breccia M; Fazi P; Vignetti M; Di Raimondo F; Sborgia M; Vincelli D; Candoni A; Salvi F; Rupoli S; Martinelli G; Kropp MG; Tonso A; Venditti A; Melillo L; Cimino G; Petti MC; Avvisati G; Lo-Coco F; Mandelli F;
    Br J Haematol; 2011 Sep; 154(5):564-8. PubMed ID: 21751984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
    Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
    J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
    Diverio D; Rossi V; Avvisati G; De Santis S; Pistilli A; Pane F; Saglio G; Martinelli G; Petti MC; Santoro A; Pelicci PG; Mandelli F; Biondi A; Lo Coco F
    Blood; 1998 Aug; 92(3):784-9. PubMed ID: 9680345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
    Lo-Coco F; Avvisati G; Vignetti M; Breccia M; Gallo E; Rambaldi A; Paoloni F; Fioritoni G; Ferrara F; Specchia G; Cimino G; Diverio D; Borlenghi E; Martinelli G; Di Raimondo F; Di Bona E; Fazi P; Peta A; Bosi A; Carella AM; Fabbiano F; Pogliani EM; Petti MC; Amadori S; Mandelli F;
    Blood; 2010 Oct; 116(17):3171-9. PubMed ID: 20644121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.
    Di Bona E; Avvisati G; Castaman G; Luce Vegna M; De Sanctis V; Rodeghiero F; Mandelli F
    Br J Haematol; 2000 Mar; 108(4):689-95. PubMed ID: 10792270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
    Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama K; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake S; Suzushima H; Emi N; Ohno R
    J Clin Oncol; 1998 Jan; 16(1):78-85. PubMed ID: 9440726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
    Tsimberidou AM; Tirado-Gomez M; Andreeff M; O'Brien S; Kantarjian H; Keating M; Lopez-Berestein G; Estey E
    Leuk Lymphoma; 2006 Jun; 47(6):1062-8. PubMed ID: 16840198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.